Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer-Reference-Cited by-同舟云学术

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

Published:2017-05-02 Issue:6 Volume:127 Page:2326-2338
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Norris John D.,Ellison Stephanie J.,Baker Jennifer G.,Stagg David B.,Wardell Suzanne E.,Park Sunghee,Alley Holly M.,Baldi Robert M.,Yllanes Alexander,Andreano Kaitlyn J.,Stice James P.,Lawrence Scott A.,Eisner Joel R.,Price Douglas K.,Moore William R.,Figg William D.,McDonnell Donald P.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/87328/files/pdf

Reference60 articles.

1. Cancer statistics, 2015

2. Evolution of androgen receptor targeted therapy for advanced prostate cancer

3. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

4. Molecular determinants of resistance to antiandrogen therapy

5. Androgen Levels Increase by IntratumoralDe novoSteroidogenesis during Progression of Castration-Resistant Prostate Cancer

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Essential Oil Components on the Activity of Steroidogenic Cytochrome P450;Biomolecules;2024-02-08

2. PC Kz is the novel human prostate cancer model in vitro and in vivo;Russian Journal of Oncology;2023-12-20

3. Breast Cancer Treatment: To tARget or Not? That Is the Question;Cancers;2023-11-30

4. Essential oil terpenes may inhibit steroidogenic cytochrome P450 activities;2023-11-02

5. Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer;Cancers;2023-10-18